spacer
home > pmps > spring 2017 > security breach
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Security Breach

Approximately 40% of all pharmaceutical products available in the US are manufactured outside of the country. It is thought that 80% of the active ingredients in drugs are made and delivered from all over the world, and these must meet the country-specific regulatory requirements of the locations in which they are going to be sold. This highlights the complexity of the industry’s supply chain.

Like many high-value commodities, pharmaceuticals are attractive to criminals – whether they are online hackers or opportunistic individuals who hijack a truck and remove its goods – with no concern whether they are life-saving drugs, prescription medication or lifestyle products.

Negating threats means thoroughly assessing your entire distribution network to determine penetration points. This can include screening vendors to ensure that they have the proper cybersecurity measures in place; scrutinising physical vulnerabilities along the route where goods can be tampered with; and identifying countries and regions with high risks for disruptions to business continuity that can potentially impact your ability to get products from point A to B.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Steve Ward serves as Vice President for the Global Intellectual Property Protection division at Pinkerton, a global provider of corporate risk management services including security consulting, investigations, executive protection, employment screening, protective intelligence and more.
spacer
Steve Ward
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Business Continuity Plan - Message from Protagen Protein Services (PPS)

Following the recent COVID-19 outbreak, we at Protagen Protein Services (PPS) are preparing for all eventualities. Please be assured that PPS will continue to operate as normal providing you with all of the professional support and service you have to come to expect from us. Given the gravity of the situation, and to protect our staff, clients, and communities from the spread of the virus, we have taken various measures within a scope of a Business Continuity Plan:
More info >>

White Papers

Clinical Trials in Russia Orange Paper: 1st Quarter 2014

Synergy Research Group

In summary, Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement